CTI Biopharma initiates phase 3 PRE-VENT study of pacritinib in hospitalised patients with severe COVID-19

Press/Media

Period29 Apr 2020

Media coverage

2

Media coverage

  • TitleCTI Biopharma initiates phase 3 PRE-VENT study of pacritinib in hospitalised patients with severe COVID-19
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date29/04/20
    URLwww.pharmabiz.com/NewsDetails.aspx?aid=123765&sid=2
    PersonsJohn Mascarenhas
  • TitleCTI Biopharma initiates phase 3 PRE-VENT study of pacritinib in hospitalised patients with severe COVID-19
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date29/04/20
    PersonsJohn Mascarenhas